Comparison ASP Herceptin vs biosimilars in the U.S. Q2 2020
As of Q2 2020, the average sales price of cancer drug Herceptin was around 4,129 U.S. dollars, compared to 3,927 U.S. dollars for biosimilar drug Hderzuma. Thus, biosimilars were able to reduce the price between 5 and 23 percent. This statistic illustrates a comparison of the ASP of Herceptin vs biosimilars in the United States.